Wilmington, Delaware — According to state and local economic development sources Incyte plans to invest $50,000,000.00 to build out 200,000 square feet of new space in Wilmington. The company plans to occupy the new space at 1801 Augustine Cut-Off in Wilmington, on or about December 1, 2021. According to the company website Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ more than 1,400 people and have operations in the U.S., Europe and Japan. Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.

To learn more about Incyte, visit http://www.incyte.com/

Company Contact:
Herve Hoppenot, President and Chief Executive Officer
https://www.linkedin.com/in/herve-hoppenot-4b912b9/
302-498-6700

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved